SciSparc Receives Notification From Nasdaq Regarding Minimum Bid Price Compliance
SciSparc Receives Notification From Nasdaq Regarding Minimum Bid Price Compliance
SciSparc Ltd. (NASDAQ:SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system (the "Company" or "SciSparc"), today announced it has received a written notice (the "Notice") from Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a period of 180 calendar days to regain compliance with the minimum bid price requirement. The Notice has no immediate effect on the Company's Nasdaq listing or the trading of its ordinary shares, and during the grace period, as may be extended, the Company's ordinary shares will continue to trade on Nasdaq under the symbol "SPRC".
SciSparc有限公司（纳斯达克股票代码：SPRC）是一家专注于开发治疗中枢神经系统障碍和罕见疾病的特殊临床阶段药品公司（以下简称“公司”或“SciSparc”），今天宣布收到了纳斯达克证券交易所（“纳斯达克”）发出的书面通知（以下简称“通知”）。通知表示公司未符合纳斯达克规则5550(a)(2)规定的持续上市最低买盘价要求，该规则要求上市证券的最低买盘价维持在每股1.00美元以上。根据纳斯达克规则5810(c)(3)(A)，公司获得了180个日历日的期限来恢复符合最低买盘价要求。通知对公司的纳斯达克上市或其普通股的交易没有立即影响，在容忍期内（如可能会延长）公司的普通股将继续在纳斯达克交易，交易符号为“SPRC”。